Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17732557 | 0.85 | ALDH1A1 (0.46) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL16436144 | 0.81 | TERT (0.32) | DUT | |
| SCHEMBL19871166 | 0.78 | — | — | |
| SCHEMBL12583029 | 0.73 | — | — | |
| SCHEMBL23134784 | 0.72 | ALDH1A1 (0.36) | DUTALDH1A1LMNAALBPOLB | |
| SCHEMBL19871074 | 0.71 | DUT (0.31) | DUTALDH1A1LMNAALBPOLB | |
| SCHEMBL12583027 | 0.71 | — | — | |
| SCHEMBL17232094 | 0.71 | CYP3A4 (0.31) | — | |
| SCHEMBL12583034 | 0.70 | — | — | |
| SCHEMBL12583051 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044327-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2018-02-15 | — | — | US | disclosed |
| US-9624249-B2 | Nucleoside kinase bypass compositions and methods | MERCK SHARP & DOHME CORP. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160263114-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2016-09-15 | — | — | US | disclosed |
| US-9326983-B2 | Compositions and methods for treating retinal degradation | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150038446-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044327-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION | POLRMT, TXNRD2, RNASE1 | DUT 1454/4885ALDH1A1 1424/4885LMNA 50/4885 |
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | DCK, DTYMK, TK1 | DUT 78/4885ALDH1A1 1490/4885LMNA 4073/4885 |
| US-20160263114-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION | ALDH1A2, UNG, DNASE1L3 | DUT 53/4885ALDH1A1 516/4885LMNA 298/4885 |
| US-20150038446-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION | ALDH1A2, UNG, DNASE1L3 | DUT 53/4885ALDH1A1 516/4885LMNA 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.